Latest news with #CHF8.25
Yahoo
04-05-2025
- Business
- Yahoo
Interested In Kuehne + Nagel International's (VTX:KNIN) Upcoming CHF08.25 Dividend? You Have Four Days Left
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Kuehne + Nagel International AG (VTX:KNIN) is about to go ex-dividend in just 4 days. The ex-dividend date generally occurs two days before the record date, which is the day on which shareholders need to be on the company's books in order to receive a dividend. It is important to be aware of the ex-dividend date because any trade on the stock needs to have been settled on or before the record date. Thus, you can purchase Kuehne + Nagel International's shares before the 9th of May in order to receive the dividend, which the company will pay on the 13th of May. The company's next dividend payment will be CHF08.25 per share, on the back of last year when the company paid a total of CHF8.25 to shareholders. Calculating the last year's worth of payments shows that Kuehne + Nagel International has a trailing yield of 4.3% on the current share price of CHF0191.30. If you buy this business for its dividend, you should have an idea of whether Kuehne + Nagel International's dividend is reliable and sustainable. So we need to check whether the dividend payments are covered, and if earnings are growing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Its dividend payout ratio is 82% of profit, which means the company is paying out a majority of its earnings. The relatively limited profit reinvestment could slow the rate of future earnings growth. It could become a concern if earnings started to decline. That said, even highly profitable companies sometimes might not generate enough cash to pay the dividend, which is why we should always check if the dividend is covered by cash flow. It paid out 81% of its free cash flow as dividends, which is within usual limits but will limit the company's ability to lift the dividend if there's no growth. It's positive to see that Kuehne + Nagel International's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut. View our latest analysis for Kuehne + Nagel International Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Stocks in companies that generate sustainable earnings growth often make the best dividend prospects, as it is easier to lift the dividend when earnings are rising. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. This is why it's a relief to see Kuehne + Nagel International earnings per share are up 8.7% per annum over the last five years. Decent historical earnings per share growth suggests Kuehne + Nagel International has been effectively growing value for shareholders. However, it's now paying out more than half its earnings as dividends. If management lifts the payout ratio further, we'd take this as a tacit signal that the company's growth prospects are slowing. Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Kuehne + Nagel International has delivered an average of 1.7% per year annual increase in its dividend, based on the past 10 years of dividend payments. Is Kuehne + Nagel International an attractive dividend stock, or better left on the shelf? Earnings per share have been growing modestly and Kuehne + Nagel International paid out a bit over half of its earnings and free cash flow last year. Overall, it's hard to get excited about Kuehne + Nagel International from a dividend perspective. With that being said, if dividends aren't your biggest concern with Kuehne + Nagel International, you should know about the other risks facing this business. For example, we've found 1 warning sign for Kuehne + Nagel International that we recommend you consider before investing in the business. Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
16-03-2025
- Business
- Yahoo
DocMorris AG (VTX:DOCM) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
It's been a sad week for DocMorris AG (VTX:DOCM), who've watched their investment drop 19% to CHF16.60 in the week since the company reported its yearly result. The statutory results were mixed overall, with revenues of CHF1.0b in line with analyst forecasts, but losses of CHF8.25 per share, some 9.0% larger than the analysts were predicting. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. View our latest analysis for DocMorris Taking into account the latest results, the consensus forecast from DocMorris' ten analysts is for revenues of CHF1.21b in 2025. This reflects a decent 19% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 20% from last year to CHF6.62. Before this earnings announcement, the analysts had been modelling revenues of CHF1.22b and losses of CHF6.27 per share in 2025. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although revenue forecasts held steady, the consensus also made a pronounced increase to its losses per share forecasts. The consensus price target held steady at CHF35.60, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on DocMorris, with the most bullish analyst valuing it at CHF60.00 and the most bearish at CHF20.00 per share. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates. Of course, another way to look at these forecasts is to place them into context against the industry itself. For example, we noticed that DocMorris' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 19% growth to the end of 2025 on an annualised basis. That is well above its historical decline of 11% a year over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 5.0% annually. So it looks like DocMorris is expected to grow faster than its competitors, at least for a while. The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at DocMorris. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for DocMorris going out to 2027, and you can see them free on our platform here.. You should always think about risks though. Case in point, we've spotted 2 warning signs for DocMorris you should be aware of, and 1 of them is concerning. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
14-03-2025
- Business
- Yahoo
DocMorris Full Year 2024 Earnings: EPS Misses Expectations
Revenue: CHF1.03b (up 6.5% from FY 2023). Net loss: CHF97.3m (loss narrowed by 17% from FY 2023). CHF8.25 loss per share (improved from CHF10.07 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.0%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Performance of the market in Switzerland. The company's shares are down 26% from a week ago. It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with DocMorris (at least 1 which doesn't sit too well with us), and understanding them should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
